Grail Trading Halted Ahead of FDA AdCom on Galleri Blood Test
GRAL has more than doubled off its 52-week low of $41.5 on elevated volume (4.0× avg).
Summary
Trading in Grail is halted ahead of today's FDA advisory committee meeting on Galleri, its multi-cancer early detection blood test. The halt follows a 34% surge this week after FDA briefing documents released Monday were more favorable than expected. RBC analyst Dan Leonard notes the FDA appears less concerned with safety and effectiveness and more focused on labeling, which suggests a potential path to approval. The AdCom vote today is the key event; a positive recommendation would likely clear the way for FDA approval and could drive further gains. This follows the positive briefing document news from Sept. 21 and adds the trading halt and analyst interpretation as new developments.
At the time of this announcement, GRAL was trading at $109.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.8B. The 52-week trading range was $41.50 to $118.84. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.